[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@pick1998_2 Nick zheng
Nick zheng posts on X about discount, $clrb, c3, $apls the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX +206%
- X Months XXXXXX +373%
- X Year XXXXXX -XX%
Mentions: X #
- X Week X no change
- X Month XX +33%
- X Months XX +600%
- X Year XX no change
Followers: XXXXX #
- X Week XXXXX +0.36%
- X Month XXXXX +1.50%
- X Months XXXXX +4.50%
- X Year XXXXX +6.10%
CreatorRank: XXXXXXXXX #
Social Influence #
Social topic influence discount, $clrb, c3, $apls
Top accounts mentioned or mentioned by @fireworkstrades @nolastevedore @jfais20 @jdbell20 @mattnachtrab @lcccc333 @ascendingbio @biotechnerd1 @af2communicate @bymadeleinea @evaluatevantage @jq1234t @juhwa18 @jul05310473john @bioclouseau @maxoluibikunle @adamfeuerstein @achillestxcom @melvinriskmgmt @lramseu
Top assets mentioned Apellis Pharmaceuticals, Inc. Common Stock (APLS)
Top Social Posts #
Top posts by engagements in the last XX hours
"$CLRB insiders are buying after r-split and financing at discount. Will FDA BTD bring this biotech stock back to life"
@pick1998_2 on X 2025-07-03 16:55:43 UTC 6931 followers, 1462 engagements
"$APLS PUDFA 7/28/25 sNDA of EMPAVELI(pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) which are severe and rare kidney diseases. Priority Review. Approval should come. It should help reach profitability" @pick1998_2 on X 2025-07-18 15:32:36 UTC 6927 followers, 1251 engagements